108 related articles for article (PubMed ID: 22726069)
1. Pleomorphic carcinoma of the breast with expression of macrophage markers: report of two cases.
Córdoba A; Del Rosario Mercado M; Vicente F; Ederra M; Torrea N; Guerrero-Setas D
Pathol Int; 2012 Jul; 62(7):491-5. PubMed ID: 22726069
[TBL] [Abstract][Full Text] [Related]
2. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
3. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
4. Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation.
Shien T; Tashiro T; Omatsu M; Masuda T; Furuta K; Sato N; Akashi-Tanaka S; Uehara M; Iwamoto E; Kinoshita T; Fukutomi T; Tsuda H; Hasegawa T
J Clin Pathol; 2005 Dec; 58(12):1299-304. PubMed ID: 16311351
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
[TBL] [Abstract][Full Text] [Related]
6. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.
Choi Y; Kim EJ; Seol H; Lee HE; Jang MJ; Kim SM; Kim JH; Kim SW; Choe G; Park SY
Hum Pathol; 2012 Jan; 43(1):48-55. PubMed ID: 21733550
[TBL] [Abstract][Full Text] [Related]
7. CD109 expression in basal-like breast carcinoma.
Hasegawa M; Moritani S; Murakumo Y; Sato T; Hagiwara S; Suzuki C; Mii S; Jijiwa M; Enomoto A; Asai N; Ichihara S; Takahashi M
Pathol Int; 2008 May; 58(5):288-94. PubMed ID: 18429827
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
9. Pleomorphic ductal carcinoma of the breast with predominant micropapillary features.
Lenicek T; Szerda F; Demirović A; Mijić A; Kruslin B; Tomas D
Pathol Int; 2007 Oct; 57(10):694-7. PubMed ID: 17803659
[TBL] [Abstract][Full Text] [Related]
10. Basal cytokeratin expression in relation to biological factors in breast cancer.
Kuroda H; Ishida F; Nakai M; Ohnisi K; Itoyama S
Hum Pathol; 2008 Dec; 39(12):1744-50. PubMed ID: 18755493
[TBL] [Abstract][Full Text] [Related]
11. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
12. Pleomorphic carcinoma with osteoclastic giant cells of the breast: immunohistochemical differentiation between coexisting neoplastic and reactive giant cells.
Kurokawa K; Mouri Y; Asano A; Kamei K; Iwata Y; Isogai M; Saga S; Ichihara S
Pathol Int; 2009 Feb; 59(2):91-7. PubMed ID: 19154262
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
14. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
15. Breast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases.
Gwin K; Wheeler DT; Bossuyt V; Tavassoli FA
Int J Surg Pathol; 2010 Feb; 18(1):27-35. PubMed ID: 19282292
[TBL] [Abstract][Full Text] [Related]
16. Centrally necrotizing carcinoma of the breast: clinicopathological analysis of 33 cases indicating its basal-like phenotype and poor prognosis.
Yu L; Yang W; Cai X; Shi D; Fan Y; Lu H
Histopathology; 2010 Aug; 57(2):193-201. PubMed ID: 20716161
[TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
18. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
19. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features.
Palacios J; Benito N; Pizarro A; Suárez A; Espada J; Cano A; Gamallo C
Am J Pathol; 1995 Mar; 146(3):605-12. PubMed ID: 7534041
[TBL] [Abstract][Full Text] [Related]
20. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
